In a report released today, Brandon Vazquez from William Blair maintained a Buy rating on Align Tech, with a price target of $178.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Vazquez has given his Buy rating due to a combination of factors, including Align’s ability to outperform expectations despite a challenging economic backdrop. The company delivered revenue ahead of consensus, driven primarily by stronger-than-anticipated clear aligner volumes, and is seeing tangible benefits from recent product introductions and more resilient international demand versus a softer North American market.
He also highlights that these new offerings, combined with initiatives such as enhanced patient financing, doctor training, and treatment planning support, position Align to capture additional growth as conditions improve. While he notes that macroeconomic uncertainty and consumer spending trends remain the key variables for future upside, he believes the current valuation—about 15 times his 2027 EPS estimate—offers an attractive risk/reward profile, supporting his unchanged $178 price target and Buy recommendation.
In another report released on April 21, Piper Sandler also reiterated a Buy rating on the stock with a $235.00 price target.